Literature DB >> 2704897

Required duration and power determinations for historically controlled studies of survival times.

L J Emrich1.   

Abstract

This paper provides power formulae for historically controlled studies with survival time endpoints, and considers two designs. The first design involves no further follow-up of control group subjects; the second design involves collection of additional information on control group subjects who had not failed at the time of design of the prospective portion of the study. The power functions differ from those for concurrently controlled studies, since, under the first design, the control group data are constant for purposes of power calculations, while under the second design, some of the control group data are constant while the remainder are random. I contrast the required duration of these studies with the required duration for comparable concurrently controlled studies under a wide range of conditions.

Mesh:

Year:  1989        PMID: 2704897     DOI: 10.1002/sim.4780080203

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

1.  A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.

Authors:  Carol Aghajanian; Virginia Filiaci; Don S Dizon; Jay W Carlson; Matthew A Powell; Angeles Alvarez Secord; Krishnansu S Tewari; David P Bender; David M O'Malley; Ashley Stuckey; JianJiong Gao; Fanny Dao; Robert A Soslow; Heather A Lankes; Kathleen Moore; Douglas A Levine
Journal:  Gynecol Oncol       Date:  2018-05-24       Impact factor: 5.482

2.  Survival trial design and monitoring using historical controls.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  Pharm Stat       Date:  2016-06-15       Impact factor: 1.894

3.  Sample size considerations for historical control studies with survival outcomes.

Authors:  Hong Zhu; Song Zhang; Chul Ahn
Journal:  J Biopharm Stat       Date:  2015-06-22       Impact factor: 1.051

4.  Group sequential design for historical control trials using error spending functions.

Authors:  Jianrong Wu; Yimei Li
Journal:  J Biopharm Stat       Date:  2019-11-12       Impact factor: 1.051

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.